Which drug–drug interactions between chemotherapy supportive agents and ivermectin are documented in clinical literature?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Clinical literature to date documents laboratory and early clinical combination data showing ivermectin can modulate drug‑resistance mechanisms (notably P‑glycoprotein/ABCB1) and synergize with multiple chemotherapeutic agents in preclinical models; direct, peer‑reviewed reports of clinically significant pharmacokinetic drug–drug interactions between ivermectin and standard chemotherapy supportive agents in humans are not shown in the available materials [1] [2] [3] [4] [5].
1. What the literature actually documents: preclinical synergy and resistance reversal
Multiple peer‑reviewed preclinical studies report that ivermectin enhances the antitumor activity of chemotherapy agents and can reverse multidrug resistance mechanisms in cancer cells. Laboratory papers and reviews describe ivermectin reversing resistance to vincristine and adriamycin in cell and mouse models [6], synergizing with cisplatin, paclitaxel, docetaxel, gemcitabine and others in vitro or in animal models [7] [1] [8] [9], and producing additive or synergistic cytotoxicity with carboplatin/paclitaxel in 3D cultures [2]. These reports consistently link ivermectin’s chemosensitizing effects to modulation of pathways including EGFR/ERK/Akt/NF‑κB and to interactions with efflux pumps such as P‑glycoprotein/ABCB1 [6] [2] [3] [4].
2. The repeated mechanistic signal: P‑gp (ABCB1) modulation
Several studies emphasize ivermectin’s interaction with P‑glycoprotein: ivermectin can act as a substrate and inhibitor of P‑gp, which increases intracellular levels of chemotherapeutic drugs in resistant cells and thereby restores sensitivity to agents like paclitaxel and doxorubicin in model systems [2] [3] [4]. That conserved mechanistic theme explains why multiple independent groups observe ivermectin‑chemo synergy across tumor types and experimental systems [3] [2] [4].
3. Clinical data: safety signals and early combination trials, not interaction studies
Available reporting includes early human combination work—an ASCO abstract reports a phase I/II trial combining ivermectin with the checkpoint antibody balstilimab in metastatic triple negative breast cancer and concludes the regimen was “safe and well tolerated” with encouraging clinical benefit [10]. A systematic look at ivermectin‑cancer research found many preclinical studies but (as of that review) no human clinical trials testing ivermectin as a monotherapy for cancer; the review notes rising interest and ongoing trials but does not enumerate clinical DDI findings [5]. These human reports are safety/efficacy‑oriented; they do not document clinically confirmed pharmacokinetic drug–drug interactions between ivermectin and routine chemotherapy supportive medications in oncology [10] [5].
4. What is not documented in the supplied sources: supportive‑agent DDIs in humans
The supplied materials document ivermectin’s effects on tumor cell drug resistance and preclinical chemo‑synergy, but they do not present clinical pharmacokinetic interaction studies between ivermectin and typical chemotherapy supportive agents (antiemetics, colony‑stimulating factors, corticosteroids, antifungals, or strong CYP/P‑gp modulators used in supportive care). Available sources do not mention specific, clinically documented DDIs between ivermectin and oncology supportive drugs in humans [6] [2] [1] [5].
5. Practical implications for clinicians and patients
Preclinical evidence argues that ivermectin can alter intracellular chemotherapy exposure by inhibiting P‑gp and related resistance pathways, which could theoretically amplify chemo effects or toxicity; this is the explicit mechanism many papers cite [2] [4] [3]. Translating that to routine clinical practice requires human DDI and safety studies because P‑gp modulation can change systemic and tissue drug levels—an effect especially relevant when patients receive narrow‑therapeutic‑index agents or combinations with overlapping toxicities [2] [3]. The literature supplied shows experimental promise but not the clinical interaction data clinicians need to adjust dosing or manage risk [5].
6. Competing viewpoints and agenda signals in the reporting
Preclinical publications and reviews strongly emphasize repurposing potential and synergy [7] [1]. Conference abstracts and small trials highlight tolerability [10], while reviews of the field caution that most data are preclinical and that human evidence is limited [5]. Patient and social‑media interest—documented by the oncology meeting review—may be driving off‑label use and trial interest, which can create pressure to adopt combinations before definitive human interaction studies exist [5]. Readers should note that many cited studies come from in vitro or animal models; authors frequently recommend further clinical evaluation [1] [8].
7. Bottom line and recommended next steps
The literature consistently documents mechanistic and preclinical pharmacologic interactions—chiefly P‑gp/ABCB1 modulation and chemosensitization—but the supplied sources do not show peer‑reviewed clinical pharmacokinetic DDI studies between ivermectin and standard chemotherapy supportive agents in humans. Clinicians who encounter patients using ivermectin during chemotherapy should treat it as a potential chemosensitizer with unknown real‑world interaction risks and rely on clinical judgment, close monitoring, and, where possible, enrollment in controlled trials [2] [5]. For definitive DDI guidance, targeted pharmacokinetic and controlled clinical interaction studies are needed; available sources document interest and early safety signals but not conclusive human DDI data [10] [5].